Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Inflammation × Dexmedetomidine × Clear all

Phase

Status

Sponsor Class

OTHER_GOV 1 OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain, Postoperative 15 Breast Neoplasms 11 Brain Neoplasms 10 Agnosia 7 Neoplasms 6 Thyroid Neoplasms 4 Stomach Neoplasms 4 Delirium 4 Pituitary Neoplasms 3 Lung Neoplasms 3 Emergence Delirium 3 Chronic Pain 3 Supratentorial Neoplasms 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Pheochromocytoma 2 Pain, Intractable 2 Pain 2 Liver Neoplasms 2 Dexmedetomidine 2 Colorectal Neoplasms 2 Central Nervous System Diseases 2 Abdominal Neoplasms 2 Urinary Bladder Neoplasms 1 Spinal Cord Neoplasms 1 Sleep Initiation and Maintenance Disorders 1 Sleep Deprivation 1 Sigmoid Neoplasms 1 Seizures 1 Sedation 1

Interventions

Exercise 5 salicylsalicylic acid 2 palbociclib 2 Vitamin D 2 Tea 2 Tablets 2 Surgical Procedures, Operative 2 Sufentanil 2 Spironolactone 2 Resistance Training 2 Oxycodone 2 Omeprazole 2 Nutrition Assessment 2 Metformin 2 Ketorolac 2 Ibuprofen 2 Fish Oils 2 Blood Specimen Collection 2 Aspirin 2 Ascorbic Acid 2 ziprasidone 1 soybean oil, phospholipid emulsion 1 semaglutide 1 montelukast 1 microcrystalline cellulose 1 ginger extract 1 falcarinol 1 falcarindiol 1 epigallocatechin gallate 1 dapagliflozin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04106999 2022-11-03

Dexmedetomidine and HIPEC

University of British Columbia

Phase 2/3 Unknown

Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡